Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability

About this episode

Shamit Shrivastava discusses his innovative approach to assessing the developability of complex antibody formats in drug development.

As drug development pushes into more complex antibody formats, the big question is: how do you really assess developability? In this episode, host Nimish Gera speaks with Shamit Shrivastava, Ph.D., founder and CEO of Apoha, to dive into Liquid Brain, his interdisciplinary innovation that’s changing the way researchers tackle developability of challenging antibody-based drugs. Shamit breaks down what makes Liquid Brain different from traditional developability methods, reveals how it’s unlocki...

People in this episode

Host: Nimish Gera

Guest: Shamit Shrivastava

Topics covered

• antibody biophysics
• drug development
• developability assessment
• interdisciplinary innovation
• Liquid Brain

Keywords

• antibody
• biophysics
• developability
• Liquid Brain
• drug development
• innovation

Mentioned in this episode

Organizations: Apoha

More episodes of The Chain: Protein Engineering Podcast

• Episode: 86 - PANEL DISCUSSION: Near-Term Challenges for ML/AI in Biotherapeutic R&D · June 9, 2026 · 54 min
• Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating · May 12, 2026 · 47 min
• Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design · April 15, 2026 · 39 min
• Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement · March 17, 2026 · 59 min
• Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies? · February 10, 2026 · 49 min
• Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research · January 13, 2026 · 44 min